Immunologic Factors: all 3,292 studies that test it
Page 20 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSActive, not recruitingNCT03535298Phase 4
- Human IgGs and Endothelial Function in Vivo in HumansCompletedNCT03534479Not applicable
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisActive, not recruitingNCT03523858Phase 3
- Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaTerminatedNCT03520985Phase 2
- Towards Personalized Dosing of Natalizumab in Multiple SclerosisCompletedNCT03516526Phase 4
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
- Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous SystemCompletedNCT03495960Phase 2
- Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral ImmunodeficiencyWithdrawnNCT03492710Phase 3
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingNCT03477500Phase 3
- Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingNCT03474744Phase 2
- Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant RecipientsStatus unknownNCT03470961Phase 4
- A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLActive, not recruitingNCT03467867Phase 2
- Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaStatus unknownNCT03456466Phase 1/2
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- A Pilot Bioequivalence Study of PomalidomideCompletedNCT03424928Phase 1
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- Subcutaneous Ig in Allogeneic Stem Cell Transplant RecipientsCompletedNCT03401268Not applicable
- Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCTStatus unknownNCT03395860Phase 2
- Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabCompletedNCT03384277Phase 4
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
- Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
- Intravenous Immunoglobulin for Unverricht-Lundborg Disease.Status unknownNCT03351569Phase 3
- Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
- A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)Status unknownNCT03348618Phase 4
- Safety of HMA-CD20 in Patients With HFrEFStatus unknownNCT03332888Phase 2
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsCompletedNCT03315923Phase 2/3
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeStatus unknownNCT03298698Phase 3
- Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidActive, not recruitingNCT03295383Phase 3
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Immunoadsorption Therapy in Managing NMDAR Antibodies EncephalitisCompletedNCT03274375Phase 2
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingNCT03269669Phase 2
- The Study of Different Dose Rituximab in the Treatment of ITPCompletedNCT03258866Phase 4
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
- The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)CompletedNCT03242460Phase 2
- Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital TraumaWithdrawnNCT03240822Phase 1
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
- Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by ChemiotherapyTerminatedNCT03225924Phase 1/2
- Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
- Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous IgCompletedNCT03211065Phase 2/3
- Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male VolunteersCompletedNCT03208218Phase 1
- IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2Active, not recruitingNCT03194815Phase 2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCTStatus unknownNCT03190733Phase 4
- Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaTerminatedNCT03189836Phase 1
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisStatus unknownNCT03180723Phase 3
- Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation FailureCompletedNCT03174964Phase 2
- Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy LossCompletedNCT03174951Phase 2
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedNCT03173092Phase 4
- Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia MajorStatus unknownNCT03171831Phase 4
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
- Panzyga in CIDP Administered at Different Infusion RatesStatus unknownNCT03166527Phase 3
- Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.CompletedNCT03164473Phase 3
- A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid ArthritisTerminatedNCT03161457Phase 1
- Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasCompletedNCT03161054Phase 2
- Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune ThrombocytopeniaCompletedNCT03154385Not applicable
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT03143985Phase 1
- Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility DiseaseStatus unknownNCT03130517Early Phase 1
- Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationWithdrawnNCT03121079Not applicable
- Study of Pomalidomide in Anal Cancer PrecursorsStatus unknownNCT03113942Phase 2
- Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's SyndromeCompletedNCT03113695Phase 1
- Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney TransplantCompletedNCT03099122Phase 4
- Inflammatory Response In SchizophreniaCompletedNCT03093064Phase 1
- Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive RegimenStatus unknownNCT03088280Phase 4
- Rituximab in Patients With Acute ST-elevation Myocardial Infarction StudyCompletedNCT03072199Phase 1/2
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedNCT03069703Phase 2
- Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha InterferonCompletedNCT03069248Phase 2
- Sargramostim for Myeloid Dendritic Cell DeficiencyTerminatedNCT03063242Phase 2
- Rituximab Objective Outcome Measures Trial in SLEStatus unknownNCT03054259Phase 2
- Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone LymphomaCompletedNCT03031483Phase 2
- Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1CompletedNCT03018652Phase 2
- Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous NephropathyStatus unknownNCT03018535Phase 3
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- The PROLONG Trial - Rituximab Maintenance Therapy in ITPCompletedNCT03010202Phase 3
- Single Dose Study of ANX005 in Healthy VolunteersTerminatedNCT03010046Phase 1
- Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's DiseaseCompletedNCT03008161Phase 1
- Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant PatientsCompletedNCT03006419Phase 4
- Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar ProteinosisCompletedNCT03006146Phase 1
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaCompletedNCT03003039Phase 1
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy LossStatus unknownNCT02990403Phase 4
- Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung DiseasesCompletedNCT02990286Phase 3